Our mission is to educate 75 PhD graduates who will transform medicines design of the 21st century. Our graduates will be leaders of medicines research and development in the UK and Ireland pharmaceutical and healthcare industry. They will have unique knowledge and skill-set to take active molecules from drug discovery and design technologies to transform these molecules in medicines to treat patients.
- In 2005, the University of Nottingham's School of Pharmacy was awarded £2.5 million for a centre of excellence in Targeted Therapeutics. Funded by AstraZeneca and the Engineering and Physical Sciences Research Council (EPSRC), this was the first Centre for Doctoral Training (CDT) to be established in direct collaboration with an industry partner.
- In 2012 the CDT expanded as the University of Nottingham and AstraZeneca were joined in partnership by University College London’s School of Pharmacy and five additional industry partners: Boots, Pfizer, GlaxoSmithKline, Quotient Clinical, and Molecular Profiles.
- In October 2014, together with industrial partners, we launched the EPSRC funded CDT in Advanced Therapeutics & Nanomedicines, welcoming 12 new PhD students each year. In 2017, Quotient Sciences, Croda and Evonik joined the CDT as partners.
- In February 2019, we obtained EPSRC funding for the CDT in Transformative Pharmaceutical Technologies, a joint venture between University of Nottingham, University College London, our partner in Ireland, Synthesis and Solid State Pharmaceutical Centre (SSPC) at Trinity College Dublin, our industrial partners: AstraZeneca, GSK, Quotient Scientific, Upperton, Nemaura, Croda, BioCity, BioNano Consulting, Arcinova, Juniper, Pfizer, Syngenta and 3M, and with a support from Academy of Pharmaceutical Sciences UK and Medicines Manufacturing Industrial Partnership.